Vasco C. Romão

POS1366 INTEROBSERVER VARIABILITY IN SYNOVIAL TISSUE BIOPSY MARKERS: RESULTS FROM OMERACT SPECIAL INTEREST GROUP ON SYNOVIAL TISSUE BIOPSY

Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework

POS1237 PERIPHERAL NERVOUS SYSTEM INVOLVEMENT OF SJÖGREN DISEASE: CHARACTERIZATION AT THE TIME OF DIAGNOSIS IN 16,703 PATIENTS FROM THE SJÖGREN BIG DATA REGISTRY

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials

ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET

Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

FRI0607 IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET

Sjögren’s syndrome: state of the art on clinical practice guidelines